Coherus BioSciences (NASDAQ:CHRS – Get Rating) issued its earnings results on Thursday. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.17, Fidelity Earnings reports. Coherus BioSciences had a negative return on equity of 211.68% and a negative net margin of 69.24%. During the same quarter in the previous year, the company earned ($0.40) EPS.
Coherus BioSciences Stock Up 11.8 %
NASDAQ CHRS traded up $1.25 during trading on Friday, hitting $11.83. The stock had a trading volume of 1,711,200 shares, compared to its average volume of 983,330. The company has a market capitalization of $915.91 million, a PE ratio of -4.33 and a beta of 1.19. The company’s 50-day moving average price is $7.82 and its two-hundred day moving average price is $10.00. The company has a debt-to-equity ratio of 33.47, a quick ratio of 3.09 and a current ratio of 3.33. Coherus BioSciences has a 12 month low of $5.60 and a 12 month high of $19.32.
Analysts Set New Price Targets
Several research firms have recently weighed in on CHRS. Barclays cut their price objective on Coherus BioSciences from $20.00 to $15.00 in a report on Monday, May 9th. Mizuho cut their price objective on Coherus BioSciences from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, May 20th. UBS Group began coverage on Coherus BioSciences in a report on Monday, June 13th. They set a “neutral” rating and a $7.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Coherus BioSciences in a report on Tuesday, May 3rd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Coherus BioSciences presently has an average rating of “Moderate Buy” and an average target price of $19.00.
Institutional Investors Weigh In On Coherus BioSciences
Coherus BioSciences Company Profile
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis.
- Get a free copy of the StockNews.com research report on Coherus BioSciences (CHRS)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.